Planegg/Martinsried - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, will participate at the following upcoming financial and scientific conferences. Medigene's management and/or scientists will be available for one-on-one meetings at these events.

CAR-TCR Summit

31 August - 2 September 2021

W: https://car-tcr-summit.com

H.C. Wainwright 23rd Annual Global Investment Conference

13-15 September 2021

W: https://hcwevents.com/annualconference

ESMO Congress

16-21 September 2021

web: https://www.esmo.org/meetings/esmo-congress-2021

Baader Investment Conference

20-24 September 2021

web: https://www.baaderinvestmentconference.com

About Medigene

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Planegg/Martinsried near Munich, Germany. With its scientific expertise, Medigene is working on the development of innovative immunotherapies to enhance T cell activity against solid cancers in fields of high unmet medical need. Medigene's pipeline includes pre-clinical as well as clinical programs in development.

Medigene's strategy is to develop its own therapies towards clinical proof-of-concept. In addition, the Company offers selected partners the opportunity to discover and develop therapies on the basis of its proprietary technology platforms. In return for such partnerships, Medigene expects to receive upfront and milestone payments as well as research and development funding and royalties on future product sales.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact:

Medigene

Dr. Anna Niedl

Phone: +49 89 2000 3333 01

E-mail: investor@medigene.com

LifeSci Advisors

Mary-Ann Chang

Phone: +44 7483 284 853

E-mail: mchang@lifesciadvisors.com

(C) 2021 Electronic News Publishing, source ENP Newswire